FDA approves AstraZeneca ’s faslodex for expanded use in breast cancer

AstraZeneca ’s faslodex (fulvestrant) at 500mg has received approval from the US Food and Drug Administration (FDA) as monotherapy for expanded use in women with advanced breast cancer.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news